SB-209509/VML-251. Antimigraine. 5-HT (1B/1D) receptor agonist

Drugs of the Future

Volumn 22, Issue 7, 1997, Pages 725-728

  Graul, A ^a   Leeson, P ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMIGRAINE AGENT; FROVATRIPTAN; RECEPTOR SUBTYPE; SEROTONIN 1D RECEPTOR; SEROTONIN AGONIST; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG;

BASILAR ARTERY; CORONARY ARTERY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; ENANTIOMER; HUMAN; IN VITRO STUDY; MIGRAINE; NONHUMAN; ORAL DRUG ADMINISTRATION; SHORT SURVEY; VASOCONSTRICTION;

EID: 0030815966     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1997.022.07.994923     Document Type: Short Survey

References (16)

1. 1 receptor agonists. EP 591280, JP 94508827, US 5464864, WO 9300086.
2. 1-like agonist is indicated. EP 603432.
3. 1-like agonists. EP 674621, JP 96504790, WO 9414772.
4. Prous, J.R. Antimigraine drugs. In: The Year's Drug News - Therapeutic Targets, 1995 Edition, Prous Science Publishers, Barcelona, 1995, 15-8.
5. Ngo, J., Mealy, N., Castañer, J. Zolmitriptan. Drugs Fut 1997, 22: 260-9.
6. 1D receptors. Brit J Pharmacol 1996, 119(Suppl.): Abst 110P.
7. Raval, P., Tilford, N.S., Smith, S.J., Porter, R., King, F.D., Kaumann, A.J., Hunter, A.J., Parsons, A.A. A comparison of the agonist profile of SB 209509 (VML 251) and sumatriptan in human isolated basilar and coronary arteries. Brit J Pharmacol 1996, 119(Suppl.): Abst 111P.
8. Parsons, A.A., Parker, S.G., Raval, P., Campbell, C.A., Hunter, A.J., Hamilton, T.C., King, F.D. Comparison of the cardiovascular effects of SB 209509 (VML 251) and sumatriptan in dogs. Brit J Pharmacol 1996, 119(Suppl.): Abst 109P.
9. Parsons, A.A., Raval, P., Tilford, N.I., Kaufmann, A.J., Hamilton, T.C., Valocik, R., Feuerstein, G., Hunter, A.J. Effects of the novel antimigraine drug, SB 209509 (VML 251) in the coronary circulation. Cephalalgia 1997, 17(3): 395.
10. Acton, G. SB 209509: Preclinical profile, pharmacological potential and clinical efficacy to date. IBC Int Conf Adv Treat Ther Dev Migraine (July 25-26, Boston) 1996.
11. Vanguard Medica and SmithKline Beecham collaborate on antimigraine drug. Comapnies will address an expanding $ 1.5 billion marketplace. SmithKline Beecham Press Release 1994, November 30.
12. 1B/1D agonist for the treatment of acute migrine. Cephalalgia 1997, 17(3): 418.
13. Vanguard Medica Product Pipeline 1996, May.
14. Vanguard Medica to take antimigraine drug to phase III clinical trials. Vanguard Medica Group pic Press Release 1996, November 18.
15. SmithKline Beecham Company Communication 1997, March 12.
16. Vanguard Medica reports successful initial phase II study for antimigraine compound. Vanguard Medica Ltd. Press Release 1996, March 25.